The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Lu, Shasha; Xu, Yu; Mu, Qitian; Cao, Lihong; Chen, Jian; Zhu, Zhijuan; Lou, Yinjun; Meng, Haitao; Qian, Wenbin; Tong, Hongyan; Mai, Wenyuan; Huang, Jian; Yu, Wenjuan; Zhao, Xiaoying; Jin, Jie
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 4(2015:Apr.)
• Page Start: 1027
• Page End: 1032
• Publication Date: 2015-04
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.947606
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>The risk factors and the role of prophylactic antiviral therapy of hepatitis B virus (HBV) reactivation in patients with hepatitis B surface antigen (HBsAg) negative/hepatitis B core antibody (HBcAb) positive disease remain controversial. We reviewed 629 patients with diffuse large B-cell lymphoma (DLBCL). Among 629 patients, 150 of 246 patients with resolved HBV (HBsAg negative and HBcAb positive) were treated with rituximab-combined therapy. Among these 150 patients, none of 104 patients (0.0%) who were hepatitis B surface antibody (HBsAb) positive experienced HBV reactivation versus four of 46 patients (8.7%) who were HBsAb negative (<italic>p</italic> = 0.008). One of 113 patients (0.9%) with International Prognostic Index (IPI) 0–2 suffered HBV reactivation versus three of the remaining 37 patients (8.1%) with IPI 3–5 (<italic>p</italic> = 0.047). HBsAb and IPI are potential risk factors for HBV reactivation. The use of prophylactic agents may not be recommended for these patients until the occurrence of HBV reactivation.</p> </abstract>